Pfizer: new positive data on bivalent vaccine

(CercleFinance.com) - Pfizer and BioNTech shares are both up on Friday in New York, following the presentation of Phase 2/3 clinical data demonstrating the efficacy of their bivalent vaccine against the original Covid-19 virus and against the Omicron variant.


According to both partners, a 30 microgram booster dose of the new vaccine generated a "robust" immune response in study participants one month after injection.

According to Pfizer and BioNTech, this bivalent vaccine enabled them to develop antibodies that neutralised the BA.4 and BA.5 Omicron sub-variants approximately four times higher than the original vaccine in people over 55 years of age.


Copyright (c) 2022 CercleFinance.com. All rights reserved.